Literature DB >> 12669175

Interactions between opioids and cocaine on locomotor activity in rats: influence of an opioid's relative efficacy at the mu receptor.

Mark A Smith1, Keith A Gordon, Christopher K Craig, Paul A Bryant, M Eric Ferguson, Adam M French, Jason D Gray, Jacob M McClean, Jonathan C Tetirick.   

Abstract

RATIONALE: Cocaine and mu opioid agonists increase central dopamine concentrations and produce robust interactions at both neurochemical and behavioral levels. Although the interactions between cocaine and high-efficacy mu opioids have been well characterized, the interactions between cocaine and lower efficacy opioids have not been as extensively examined.
OBJECTIVE: The purpose of this study was to examine the interactions between cocaine and opioids possessing a range of relative efficacy at the mu receptor.
METHODS: Male, Long-Evans rats were habituated to an open-field, locomotor activity chamber, and the effects of cocaine and various opioids were tested under a cumulative dosing procedure. In this procedure, a selected dose of an opioid was administered during the first component of a session, with increasing doses of cocaine administered during subsequent components.
RESULTS: When administered alone, cocaine produced dose-dependent increases in locomotor activity that was stable across 5 weeks of behavioral testing. The high-efficacy mu opioid levorphanol, and the low-efficacy opioids buprenorphine, butorphanol, nalbuphine and (-)-pentazocine, dose-dependently enhanced the effects of cocaine at doses that did not alter locomotor activity when administered alone. In contrast, the opioid antagonist naloxone, and to a lesser extent, the kappa opioid spiradoline attenuated the effects of cocaine at doses that did not alter locomotor activity when administered alone. Across an extensive dose range, the low-efficacy opioid nalorphine failed to alter cocaine's locomotor-activating effects.
CONCLUSIONS: These data suggest that low-efficacy opioids possessing significant mu-agonist activity (e.g. buprenorphine, butorphanol, nalbuphine, (-)-pentazocine) may potentiate the effects of cocaine in a manner similar to that typically observed with high-efficacy mu opioids.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12669175     DOI: 10.1007/s00213-003-1388-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  79 in total

1.  Opioid modulation of the discriminative stimulus effects of cocaine: comparison of µ, kappa and delta agonists in squirrel monkeys discriminating low doses of cocaine.

Authors:  R.D. Spealman; J. Bergman
Journal:  Behav Pharmacol       Date:  1994-02       Impact factor: 2.293

2.  Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids.

Authors:  R D Spealman; J Bergman
Journal:  J Pharmacol Exp Ther       Date:  1992-05       Impact factor: 4.030

3.  Synergistic elevations in nucleus accumbens extracellular dopamine concentrations during self-administration of cocaine/heroin combinations (Speedball) in rats.

Authors:  S E Hemby; C Co; S I Dworkin; J E Smith
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

4.  Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay.

Authors:  D V Romero; J S Partilla; Q X Zheng; S O Heyliger; Q Ni; K C Rice; J Lai; R B Rothman
Journal:  Synapse       Date:  1999-11       Impact factor: 2.562

5.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

6.  Examination of the kappa agonist and antagonist properties of opioids in the rat drug discrimination procedure: influence of training dose and intrinsic efficacy.

Authors:  M.A. Smith; M.J. Picker
Journal:  Behav Pharmacol       Date:  1995-11       Impact factor: 2.293

7.  Buprenorphine and morphine produce equivalent increases in extracellular single unit activity of dopamine neurons in the ventral tegmental area in vivo.

Authors:  S J Grant; G Sonti
Journal:  Synapse       Date:  1994-03       Impact factor: 2.562

8.  The effects of the naltrexone implant on rodent social interactions and cocaine-induced conditioned place preference.

Authors:  L D Mitchem; C K Kruschel; E Dallman; K A Anders; M Czapiga; J J Panos; R E Steinpreis
Journal:  Pharmacol Biochem Behav       Date:  1999-01       Impact factor: 3.533

9.  Effects of butorphanol and its metabolites on the levels of monoamines and their metabolites in the rat brain.

Authors:  M Niwa; T Nose; M Nozaki; K Tsurumi; H Fujimura
Journal:  Jpn J Pharmacol       Date:  1985-12

10.  Opioid mediation of cocaine-induced hyperactivity and reinforcement.

Authors:  A A Houdi; M T Bardo; G R Van Loon
Journal:  Brain Res       Date:  1989-09-11       Impact factor: 3.252

View more
  6 in total

1.  Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

2.  Age-dependent effects of kappa-opioid receptor stimulation on cocaine-induced stereotyped behaviors and dopamine overflow in the caudate-putamen: an in vivo microdialysis study.

Authors:  A M Cortez; S Charntikov; T Der-Ghazarian; L R Horn; C A Crawford; S A McDougall
Journal:  Neuroscience       Date:  2010-05-05       Impact factor: 3.590

3.  The effects of repeated opioid administration on locomotor activity: II. Unidirectional cross-sensitization to cocaine.

Authors:  Mark A Smith; Jennifer L Greene-Naples; Jennifer N Felder; Jordan C Iordanou; Megan A Lyle; Katherine L Walker
Journal:  J Pharmacol Exp Ther       Date:  2009-04-29       Impact factor: 4.030

4.  The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference.

Authors:  Paul Marquez; Ramkumarie Baliram; Brigitte L Kieffer; Kabirullah Lutfy
Journal:  Neuropharmacology       Date:  2007-01-20       Impact factor: 5.250

5.  The mu/kappa agonist nalbuphine attenuates sensitization to the behavioral effects of cocaine.

Authors:  M A Smith; K T Cole; J C Iordanou; D C Kerns; P C Newsom; G W Peitz; K T Schmidt
Journal:  Pharmacol Biochem Behav       Date:  2013-01-07       Impact factor: 3.533

6.  Interactions Between Opioids and Dextroamphetamine on Locomotor Activity: Influence of an Opioid's Relative Efficacy at the Mu Receptor.

Authors:  Mark A Smith; Shannon L Ballard; Clarise F Ballesteros; Samantha A Bonge; Alexander T Casimir; Lauren M Childs; Max A Feinstein; Annie K Griffith; Alexandra N Johansen; Daegeon Lee; A Caroline Mauser; Cassidy M Moses; Ian J Robertson; Javier U Robles; Justin C Strickland; Mary E Walters; Seeley J Yoo
Journal:  Front Psychiatry       Date:  2022-01-05       Impact factor: 5.435

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.